BBIO vs QQQ Stock Comparison
BBIO currently leads QQQ in this stock comparison, with AIQ scores of 64 vs 46. The clearest difference is value, while QQQ has the stronger quality profile.
What is the main difference between BBIO and QQQ?
BBIO leads the current stock comparison as BridgeBio Pharma, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
BridgeBio Pharma, Inc. vs Invesco QQQ Trust, Series 1
BBIO leads
BBIO leads by 18 AIQ points, primarily on Value and Momentum, having only recently taken the lead back from QQQ.
Fragile: 4 of 4 evidence groups support BBIO, the lead recently changed hands, and its current signal state is conflicted.
BridgeBio Pharma, Inc.
Invesco QQQ Trust, Series 1
The Algovestiq AIQ Score currently favors BBIO over QQQ, 64 versus 46 as of Nov 15, 2026. BBIO's advantage is driven primarily by stronger value and momentum, while QQQ holds the stronger quality profile. BBIO also shows the stronger technical structure relative to its 50-day moving average. 4 of 4 covered evidence groups favor BBIO today, and the comparison is rated Fragile on stability: the lead has already changed hands inside the comparison window. BBIO lead: Reversed — QQQ led by 13 AIQ points 30 sessions ago; BBIO now leads by 18.
Compare BridgeBio Pharma, Inc. and Invesco QQQ Trust, Series 1 across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare BBIO and QQQ against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value55 vs 13BBIO +42
- Momentum69 vs 33BBIO +36
- Risk Resilience62 vs 31BBIO +31
- Quality66 vs 93QQQ +27
4 of 4 evidence groups favor BBIO. BBIO’s edge is concentrated in value and momentum; QQQ keeps a meaningful quality edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Quality +1
No signal started or stopped since the prior session; its 5 active signals are unchanged.
Largest factor move: Value +1
New signals
- Price Lost 200-Day MA — bearish, trend, long horizon
- Drawdown Recovery Signal — bullish, risk_regime, long horizon (-14.8%)
BBIO's lead widened by 2 AIQ points in the latest session.
Deeper signal detail for each name lives on its own signals page — BBIO and QQQ both carry a full feed there.
The central trade-off
BBIO (BridgeBio Pharma, Inc.): the stronger current systematic profile, led by value and momentum.
QQQ (Invesco QQQ Trust, Series 1): the counter-case, on quality.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
BBIOBBIO on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
EvenGrowth figures are not covered for both names.
Value
BBIOBBIO on the peer-relative Value factor, by 42 points.
Momentum
BBIOBBIO on the Momentum factor, by 36 points.
Lower downside
BBIOBBIO on Risk Resilience, by 31 points.
Analyst upside
EvenAnalyst targets are level or not covered for both names.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | BBIO | QQQ | Note |
|---|---|---|---|
| Implied upside to target | +42% | — | Level |
| Target dispersion | +62.1% | — | Lower is tighter analyst agreement |
| Consensus | Buy | — | Context, not a primary driver |
| Analysts covering | 22 | — | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 4 covered evidence groups favor BBIO. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | BBIO | 64 vs 46 |
| Fundamentals | Not covered | Not covered |
| Valuation | BBIO | Value 55 vs 13 |
| Technicals | BBIO | Price vs 50-day 11.9% vs -5.3%; vs 200-day 7.7% vs -0.3% |
| Risk Resilience | BBIO | Risk Resilience 62 vs 31 |
| Analyst expectations | Not covered | Not covered |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BBIO and QQQ and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is wide at 18 points. (supports the conclusion holding)
- 4 of 4 covered evidence groups point the same way. (supports the conclusion holding)
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
- The lead has swung materially session to session. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BBIO.
How the comparison changed
120 daily snapshots · May 27 – Nov 13BBIO lead: Reversed — QQQ led by 13 AIQ points 30 sessions ago; BBIO now leads by 18.
- Today
- BBIO +18
- 64 vs 46
- 7 sessions ago
- BBIO +12
- 62 vs 50
- 30 sessions ago
- QQQ +13
- 50 vs 63
- 90 sessions ago
- BBIO +3
- 59 vs 56
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 2 bearish / 1 neutral, conflicted
Only BBIO
- Death Cross Active — bearish, trend, long horizon (3.88%)
- ADX Trend Strengthening — neutral, trend, medium horizon
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.38x)
- TRIX Bullish Signal — bullish, momentum, short horizon
2 bullish / 1 bearish, conflicted
Only QQQ
- Golden Cross Active — bullish, trend, long horizon (5.22%)
- Price Lost 200-Day MA — bearish, trend, long horizon
- Drawdown Recovery Signal — bullish, risk_regime, long horizon (-14.8%)
BBIO leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price and the AIQ Score both moved up over the latest session (price +0.17%, AIQ +1 points).
Price and the AIQ Score both moved down over the latest session (price -1.2%, AIQ -1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1QQQ closes the Value gap — currently 42 points behind, the largest single contributor to BBIO's edge.
- 2QQQ's Price Lost 200-Day MA resolves — a bearish trend rule currently active against it.
- 3BBIO's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
Split| Metric | BBIO | QQQ |
|---|---|---|
| Revenue growth (YoY) | 44.9% | — |
| EPS growth (YoY) | 46.2% | — |
| Gross margin | 93.5% | — |
| Operating margin | -43.4% | — |
| Return on equity (TTM) | 3.4% | — |
| Debt to equity | -1.5 | — |
Performance
BBIO leads 5 of 6 windows| Metric | BBIO | QQQ |
|---|---|---|
| 1 week (5 sessions) | 5.4% | 3.6% |
| 1 month (20 sessions) | 17.9% | -4.2% |
| 3 months (63 sessions) | -2% | -6.8% |
| 6 months (126 sessions) | 18.4% | -4.1% |
| Year to date | 2.4% | 10.7% |
| 1 year (252 sessions) | 18.2% | 9.5% |
Technicals
BBIO has the stronger structure| Metric | BBIO | QQQ |
|---|---|---|
| RSI (14) | 65 | 42.8 |
| ADX (14) | 38.9 | 30.3 |
| Price vs 50-day | 11.9% | -5.3% |
| Price vs 200-day | 7.7% | -0.3% |
| Volatility (1M, annualized) | 39.1% | 35.4% |
Risk
BBIO is the more resilient| Metric | BBIO | QQQ |
|---|---|---|
| Beta | 0.95 | 1.46 |
| Sharpe ratio | 0.55 | 0.44 |
| Sortino ratio | 0.84 | 0.62 |
| Max drawdown | -29.8% | -14.8% |
| Current drawdown | -13.2% | -10.5% |
| Annualized volatility | 44.1% | 21.5% |
| Value at risk (95%) | -4% | -2% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, BBIO or QQQ?
On the Algovestiq AIQ Score, BBIO is the stronger of the two as of Nov 15, 2026, scoring 64 against QQQ's 46. The edge comes from value and momentum. QQQ is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is BBIO or QQQ the better buy right now?
BBIO carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 4 of 4 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the lead has already changed hands inside the comparison window. Treat the lead as provisional.
Why does the AIQ Score favor BBIO over QQQ?
The composite weights Quality, Value, Momentum and Risk Resilience. BBIO leads Value by 42 points; BBIO leads Momentum by 36 points; BBIO leads Risk Resilience by 31 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, BBIO or QQQ?
Analyst price targets imply +42% upside for BBIO and not covered for QQQ. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, BBIO or QQQ?
BBIO is the better-valued of the two on the peer-relative Value factor. BBIO on the peer-relative Value factor, by 42 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, BBIO or QQQ?
Growth figures are not covered for both names. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, BBIO or QQQ?
BBIO on the Momentum factor, by 36 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, BBIO or QQQ?
BBIO is the more resilient of the two, so the other name carries the higher downside risk. BBIO on Risk Resilience, by 31 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is BBIO more profitable than QQQ?
Margin data is not comparable for both names in the current snapshot.
Is BBIO's lead over QQQ getting stronger or weaker?
BBIO lead: Reversed — QQQ led by 13 AIQ points 30 sessions ago; BBIO now leads by 18. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the BBIO vs QQQ verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: QQQ closes the Value gap — currently 42 points behind, the largest single contributor to BBIO's edge; QQQ's Price Lost 200-Day MA resolves — a bearish trend rule currently active against it; BBIO's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about BBIO and QQQ?
BBIO: 2 bullish / 2 bearish / 1 neutral, conflicted. QQQ: 2 bullish / 1 bearish, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BBIO is Death Cross Active (bearish, long horizon). On QQQ it is Golden Cross Active (bullish, long horizon).
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.